Ongoing Clinical Trials for Solitary Fibrous Tumour
There is currently 1 ongoing clinical trial for solitary fibrous tumour, investigating the use of eribulin as a second or third-line treatment option for adults with advanced disease. This trial is being conducted in Italy and aims to evaluate the effectiveness of this medication in slowing tumor growth or reducing tumor size.
Clinical trial locations
- Italy
Study of Eribulin for Adults with Advanced Solitary Fibrous Tumor in Second or Third Line Treatment
This clinical trial is examining the effectiveness of eribulin, marketed as Halaven, in treating advanced solitary fibrous tumour when used as a second or third treatment option. This type of tumour is rare and originates in connective tissue, often found in the lining of the lungs or other body areas. While these tumours typically grow slowly, they can become more aggressive in advanced stages and spread to other parts of the body.
Main inclusion criteria: To participate in this study, patients must be at least 18 years old and have a confirmed diagnosis of a STAT6 positive solitary fibrous tumour. The disease must be locally advanced, meaning it cannot be completely removed by surgery, or it has spread to other parts of the body. Patients must have already received at least one but no more than two previous treatments for their advanced disease. The tumour must be measurable, and there must be evidence that the disease has progressed within the past 6 months. Participants need to have adequate organ and bone marrow function, with a heart ejection fraction of at least 50%. Female patients of childbearing potential must have a negative pregnancy test, and all patients who can have children must agree to use effective birth control during the study.
Main exclusion criteria: The study excludes patients who have a different type of tumour than the one being studied, those who are not in their second or third line of treatment, individuals who are not adults, and those considered part of a vulnerable population who might need extra protection or care.
Trial focus and design: The study compares the effects of Halaven with a placebo to determine how well the medication works in reducing tumour size or slowing its growth. The treatment is administered as an intravenous injection in 21-day cycles, with medication given on day 1 and day 8 of each cycle. Throughout the trial, participants will be monitored using imaging techniques to evaluate their response to treatment. The treatment will continue until patients experience unacceptable side effects or their disease progresses. The trial is expected to conclude by July 31, 2025.
Investigational drug: Eribulin is a microtubule inhibitor, a type of chemotherapy agent that works by interfering with the growth of cancer cells. At the molecular level, it disrupts microtubule dynamics, which are essential for cell division, potentially helping to slow down or stop tumour progression. In this trial, it is being studied specifically for its effectiveness in managing advanced solitary fibrous tumours as a second or third-line treatment option.
Summary
Currently, there is one active clinical trial investigating treatment options for solitary fibrous tumour. This trial is being conducted in Italy and focuses on evaluating eribulin as a treatment option for patients who have already tried one or two other therapies. The study represents an important step in finding effective treatments for this rare type of tumour, particularly for patients with advanced disease. Given the rarity of this condition, participation in clinical trials like this one may provide patients with access to potentially beneficial treatment options while contributing to medical knowledge about managing this challenging disease.
